SignaBlok presented preclinical data on efficacy of ultra high sensitivity MRI contrast agent for diagnostic imaging of atherosclerosis in a non-rodent animal model at the 2017 World Molecular Imaging Congress
SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for retinopathy of prematurity at the 2017 ARVO Annual Meeting
SignaBlok presented preclinical data on further development of a novel ligand-independent inhibitor of TREM-1 for treatment of lung and pancreatic cancer at the 2017 AACR Annual Meeting
SignaBlok pitched on company’s magic bullet therapy for cancer, autoimmune diseases, atherosclerosis and retinopathy at the 2016 Life Sciences Summit
SignaBlok awarded NIAAA / NIH SBIR Phase I grant to test new approach to treatment of alcoholic liver disease
SignaBlok presented multiple applications of SCHOOL technology in drug discovery at the 2016 BIO International Convention
SignaBlok presented innovative approach to diagnostic imaging of atherosclerosis at the 2015 NHLBI Innovation Conference-West
SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for rheumatoid arthritis at the 2015 ACR Annual Meeting
SignaBlok presented preclinical data showcasing company’s peptide therapeutic programs in cancer, inflammation and autoimmune diseases at the 2015 Therapeutics Stream at the Essential Protein Engineering Summit (PEGS) Annual Meeting
